Author:
Ali M. Al‐Balkhi, Faris K. Khadir, Wameedh Q. Al-Sammak and Ameen Al-Alwany
Page: 1-5
Published online: 28 Dec 2024
https://doi.org/10.36478/aceju.2024.1.7
Levetiracetam, a newer antiepileptic drug (AED), is commonly prescribed due to its efficacy and safety profile. However, its effects on Vitamin D3 levels and bone health remain uncertain, particularly in long‐term monotherapy. This study aimed to evaluate the effects of Levetiracetam monotherapy on Vitamin D3 levels, serum calcium and alkaline phosphatase (ALP) among Iraqi patients with epilepsy. This cross‐sectional prospective study included 32 patients diagnosed with generalized or focal epilepsy. All patients received Levetiracetam monotherapy (1000‐3000) mg/day for at least 6 months. Vitamin D3 levels, calcium levels and ALP values were analyzed. Results were presented in tables, percentages and correlations with dose and duration. The results showed that(35.3%) of patients had severe Vitamin D3 deficiency (30) ng/ml were observed in only (23.5%). A strong negative correlation (R=‐0.54) was found between Vitamin D3 levels and Levetiracetam dose. Calcium deficiency was noted in (17.6%) of patients and (11.8%) had abnormal ALP levels. Levetiracetam monotherapy, particularly at higher doses, is associated with reduced Vitamin D3 levels and potential risks to bone health. Regular monitoring and supplementation are recommended to mitigate these effects.